LONDON (Reuters) - An experimental cancer drug from Britain's Antisoma Plc (ASM.L: Quote, Profile, Research) and Swiss-based Novartis AG (NOVN.VX: Quote, Profile, Research) has failed in a mid-stage clinical trial for ovarian cancer, lopping around a fifth off Antisoma's market value.
